03/27/2023: Lab Update: FDA Issues Final Guidances for COVID-19 Medical Device Transition Plans
Audience: Laboratory and Testing Professionals
Level: Laboratory Update
On March 24, 2023, the U.S. Food and Drug Administration (FDA) issued final guidances for the following transition plans:
- Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
- Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19)
The guidances outline FDA’s general recommendations to transition from certain policies adopted and operations implemented during the COVID-19 pandemic to normal operations. The recommendations include information for devices that fall within certain enforcement policies issued during the COVID-19 public health emergency (PHE) under section 319 of the Public Health Service Act and devices issued EUAs related to COVID-19 under section 564 of the Federal Food, Drug, and Cosmetic Act.
There will be a 180-day transition period for impacted devices. Manufacturers who plan to continue distributing their devices after either the end of the transition period following the expiration of the COVID-19 PHE or termination of the relevant device EUA declaration related to COVID-19 should refer to information on the scope and timeline for the transition period found in each guidance link above.
Opt in to receive emails from the CDC Laboratory Outreach Communication System (LOCS).
Laboratory Outreach Communication System | Division of Laboratory Systems (DLS)
Office of Laboratory Science and Safety (OLSS)
Centers for Disease Control and Prevention (CDC)